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Abstract 
Introduction 
We have previously shown that a tag single nucleotide polymorphism (rs10235235), which 
maps to the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary 
estrone glucuronide levels and a modest reduction in risk of breast cancer in women age ≤50 
years. 
Methods 
We further investigated the association of rs10235235 with breast cancer risk in a large case 
control study of 47,346 cases and 47,570 controls from 52 studies participating in the Breast 
Cancer Association Consortium. Genotyping of rs10235235 was conducted using a custom 
Illumina Infinium array. Stratified analyses were conducted to determine whether this 
association was modified by age at diagnosis, ethnicity, age at menarche or tumor 
characteristics. 
Results 
We confirmed the association of rs10235235 with breast cancer risk for women of European 
ancestry but found no evidence that this association differed with age at diagnosis. 
Heterozygote and homozygote odds ratios (ORs) were OR = 0.98 (95% CI 0.94, 1.01; P = 
0.2) and OR = 0.80 (95% CI 0.69, 0.93; P = 0.004), respectively (Ptrend = 0.02). There was no 
evidence of effect modification by tumor characteristics. rs10235235 was, however, 
associated with age at menarche in controls (Ptrend = 0.005) but not cases (Ptrend = 0.97). 
Consequently the association between rs10235235 and breast cancer risk differed according 
to age at menarche (Phet = 0.02); the rare allele of rs10235235 was associated with a reduction 
in breast cancer risk for women who had their menarche age ≥15 years (ORhet = 0.84, 95% CI 
0.75, 0.94; ORhom = 0.81, 95% CI 0.51, 1.30; Ptrend = 0.002) but not for those who had their 
menarche age ≤11 years (ORhet = 1.06, 95% CI 0.95, 1.19, ORhom = 1.07, 95% CI 0.67, 1.72; 
Ptrend = 0.29). 
Conclusions 
To our knowledge rs10235235 is the first single nucleotide polymorphism to be associated 
with both breast cancer risk and age at menarche consistent with the well-documented 
association between later age at menarche and a reduction in breast cancer risk. These 
associations are likely mediated via an effect on circulating hormone levels. 
Introduction 
Family history is a well-established risk factor for breast cancer. First-degree relatives of 
women with breast cancer have an approximately 2-fold increased risk of developing the 
disease relative to the general population [1]. Twin studies are consistent with this familial 
clustering having, at least in part, a genetic origin [2,3]. Mutations in high-risk susceptibility 
genes (mainly BRCA1 and BRCA2) explain most large multiple-case families, but account for 
only 15-20% of the excess familial risk [4]. Genome-wide association studies (GWAS) [5,6] 
have identified more than 70 common variants that are associated with breast cancer 
susceptibility but they account for only another approximately 15% of the excess familial 
risk. The so-called ‘missing heritability’ may be explained by common variants with very 
small effects and/or by rarer variants with larger effects, neither of which can be identified by 
current GWAS. A statistically efficient alternative is to increase power by trying to identify 
variants associated with known quantitative phenotypic markers of susceptibility to breast 
cancer [7], and then test them for association with breast cancer risk. This approach might 
also improve our understanding of the biological mechanisms involved in breast cancer 
pathogenesis. 
Endogenous sex hormones are well-established risk factors for breast cancer in 
postmenopausal women [8]; the evidence in premenopausal women is less consistent with 
some but not all studies suggesting an association between higher circulating levels of 
estrogens and increased breast cancer risk [9-17]. Genetic factors influence the levels of 
endogenous sex hormones [18] and therefore single nucleotide polymorphisms (SNPs) in 
genes regulating these hormonal pathways are good candidates for being breast cancer 
predisposition variants. We have previously studied 642 SNPs tagging 42 genes that might 
influence sex hormone levels in 729 healthy premenopausal women of European ancestry in 
relation to cyclic variations in estrogen levels during the menstrual cycle. We found that the 
minor allele of rs10273424, which maps 50 kb 3′ to CYP3A5, was associated with a reduction 
of 22% (95% confidence interval (CI) -28%, -15%; P = 10−9) in levels of urinary estrone 
glucuronide (E1G), a metabolite that is highly correlated with serum estradiol levels [19]. 
Analysis of 10,551 breast cancer cases and 17,535 controls of European ancestry 
demonstrated that the minor allele of rs10235235, a proxy for rs10273424 (r2 = 1.0), was also 
associated with a weak reduction in breast cancer risk but only in women aged 50 years or 
younger at diagnosis (odds ratio (OR) = 0.91, 95% CI 0.83, 0.99; P = 0.03) [19]. 
The aim of the present study was to further investigate an association between rs10235235 
and breast cancer risk using a much larger set of subjects - the Breast Cancer Association 
Consortium (BCAC) - comprising data from 49 additional studies, and to assess whether 
there was evidence of effect modification by age at diagnosis, ethnicity, age at menarche or 
tumour characteristics. 
Materials and methods 
Sample selection 
Samples for the case-control analyses were drawn from 52 studies participating in the BCAC: 
41 from populations of predominantly European ancestry, nine of Asian ancestry and two of 
African-American ancestry. The majority of studies were population-based or hospital-based 
case-control studies, but some studies were nested in cohorts, selected samples by age, 
oversampled for cases with a family history or selected samples on the basis of tumour 
characteristics (Additional file 1: Table S1). Studies provided ~2% of samples in duplicate 
for quality control purposes (see below). Study subjects were recruited on protocols approved 
by the Institutional Review Boards at each participating institution, and all subjects provided 
written informed consent (Additional file 2). 
Genotyping and post-genotyping quality control 
Genotyping for rs10235235 was carried out as part of a collaboration between BCAC and 
three other consortia (the Collaborative Oncological Gene-environment Study, COGS). Full 
details of SNP selection, array design, genotyping and post-genotyping quality control (QC) 
have been published [5]. Briefly, three categories of SNPs were chosen for inclusion on the 
array: (i) SNPs selected on the basis of pooled GWAS data, (ii) SNPs selected for the fine-
mapping of published risk loci and (iii) candidate SNPs selected on the basis of previous 
analyses or specific hypotheses. rs10235235 was a candidate SNP selected on the basis of our 
previous analyses [19]. For the COGS project overall, genotyping of 211,155 SNPs in 
114,225 samples was conducted using a custom Illumina Infinium array (iCOGS) in four 
centres. Genotypes were called using Illumina’s proprietary GenCall algorithm. Standard 
quality control measures were applied across all SNPs and all samples genotyped as part of 
the COGS project. Samples were excluded for any of the following reasons: genotypically 
not female XX (XY, XXY or XO, N = 298); overall call rate <95% (N = 1,656); low or high 
heterozygosity (P < 10−6, separately for individuals of European, Asian and African-
American ancestry, N = 670); individuals not concordant with previous genotyping within 
BCAC (N = 702); individuals where genotypes for the duplicate sample appeared to be from 
a different individual (N = 42); “cryptic” duplicates within studies where the phenotypic data 
indicated that the individuals were different or between studies where genotype data indicated 
samples were duplicates (N = 485); first degree relatives (N = 1,981); phenotypic exclusions 
(N = 527); concordant replicates (N = 2,629). Ethnic outliers were identified by multi-
dimensional scaling, combining the iCOGS data with the three Hapmap2 populations, based 
on a subset of 37,000 uncorrelated markers that passed QC (including ~1000 selected as 
ancestry informative markers). Most studies were predominantly of a single ancestry 
(European or Asian), and women with >15% minority ancestry, based on the first two 
components, were excluded (N = 1,244). Two studies from Singapore (SGBCC) and 
Malaysia (MYBRCA) contained a substantial fraction of women of mixed European/Asian 
ancestry (likely of South Asian ancestry). For these studies, no exclusions for ethnic outliers 
were made, but principal components analysis (see below) was used to adjust for inflation in 
these studies. Similarly, for the two African-American studies (NBHS, SCCS), no exclusions 
for ethnic outliers were made. 
Principal components analyses were carried out separately for the European, Asian and 
African-American subgroups, based on a subset of 37,000 uncorrelated SNPs. For the 
analyses of European subjects, we included the first six principal components as covariates, 
together with a seventh component derived specific to one study (LMBC) for which there 
was substantial inflation not accounted for by the components derived from the analysis of all 
studies. Addition of further principal components did not reduce inflation further. Two 
principal components were included for the studies conducted in Asian populations and two 
principal components were included for the African-American studies. 
For the main analyses of rs10235235 and breast cancer risk, we excluded women from three 
studies (BBCS, BIGGS and UKBGS) that were genotyped in the hypothesis generating study 
(N = 5,452) [19] and women with non-invasive cancers (ductal carcinoma in situ/lobular 
carcinoma in situ, N = 2,663) or cancers of uncertain status (N = 960)). After exclusions there 
were 47,346 invasive breast cancer case samples and 47,570 control samples from 49 studies 
(38 from populations of predominantly European ancestry, nine Asian and two African-
American) used in the analysis (Additional file 1: Table S1 and S2). After quality control 
exclusions (above) the call rate for rs10235235 was 100% (1 no call in 94,916 samples) and 
for the controls, there was no evidence of deviation from Hardy-Weinberg equilibrium 
(HWE) in any of the contributing studies (Additional file 1: Table S2). 
We did not test for an association between rs10235235 and age at menarche in our hypothesis 
generating study [19]. Therefore, to maximise our power to detect an association, we 
included menarche data from BBCS cases (N = 2,508) and controls (N = 1,650) and UKBGS 
cases (N = 3,388) and controls (N = 4,081) in this analysis. Age at menarche was not 
available for samples from BIGGS. Full details of genotyping of rs10235235 in BBCS and 
UKBGS samples have been published previously [19]. Briefly, genotyping was carried out 
using competitive allele-specific PCR KASPar chemistry (KBiosciences Ltd, Hertfordshire, 
UK). Call rates were 98.0% (BBCS), 96.6% (UKBGS); there was no evidence for deviation 
from HWE (P = 0.29 (BBCS); P = 0.92 (UKBGS)) and duplicate concordance based on a 1% 
(BBCS) and 5% (UKBGS) random sample of duplicates was 100% for both studies. 
Statistical analysis 
We estimated per-allele and genotypic log-odds ratios (ORs) for the European, Asian and 
African-American subgroups separately using logistic regression, adjusted for principal 
components and study [5]. To test for departure from a multiplicative model we compared 
multiplicative and unconstrained models using a 1 degree of freedom (df) likelihood ratio 
test. Heterogeneity in ORs between studies within each subgroup (European, Asian and 
African-American), and between subgroups, was assessed using the Cochrane Q statistic and 
quantified using the I2 measure [20]. 
Analyses stratified by estrogen receptor (ER) status (+/-), progesterone receptor (PR) status 
(+/-), morphology (ductal or lobular), grade (1,2,3), lymph node involvement (+/-) or age at 
diagnosis (≤50 and >50 years) were restricted to studies of European ancestry due to the 
small number of studies of Asian and African-American ancestry. In addition, studies were 
excluded if they had selected cases on the basis of the stratifying variable, or had collected 
data on that variable for less than 5% of cases or less than 10 cases in total. Availability of 
data for each of the stratifying variables in each study is shown in Additional file 1: Table S3. 
To assess the relationship between each of the stratifying variables and genotype, stratum–
specific ORs were calculated using logistic regression. Cases in each stratum were compared 
with all control subjects, adjusted for study and principal components. Case-only logistic 
regression was used to test for heterogeneity between strata (binary stratifying variables) or 
across strata (stratifying variables with three or more strata). P values were estimated using 
likelihood ratio tests with 1 df. 
We assessed whether rs10235235 was associated with age at menarche in cases and controls 
separately. Studies that had not collected data on age at menarche in both cases and controls 
were excluded (Additional file 1: Table S4). We used linear regression, adjusted for principal 
components and study, to estimate the relationship between age at menarche (in years) and 
rs10235235 genotype (0, 1, 2 rare alleles) and logistic regression adjusted for principal 
components and study to estimate the association between age at menarche and breast cancer 
risk. To test for effect modification of an association between rs10235235 and breast cancer 
risk by age at menarche we used logistic regression adjusted for principal components, study 
and age at menarche (grouped as ≤11, 12, 13, 14 and ≥15 years) with and without an 
interaction term(s). We considered four models: (i) no interaction (0 interaction terms), (ii) 
assuming a linear interaction between genotype and menarche group (1 interaction term), (iii) 
assuming a linear interaction between genotype and menarche group but allowing the linear 
term to differ between women who were heterozygous and those who were homozygous for 
the rare allele (2 interaction terms) and (iv) one interaction term for each possible 
genotype/menarche group combination (8 interaction terms). Nested models were compared 
using likelihood ratio tests. All statistical analyses were performed using STATA version 
11.0 (College Station, Texas, US). All P values reported are two-sided. 
Results 
The case-control analysis comprised genotype data for 47,346 invasive breast cancer cases 
and 47,569 controls from 49 studies, including 80,518 (84.8%) subjects of self-reported 
European ancestry, 12,419 (13.1%) of self-reported Asian ancestry and 1,978 (2.1%) of self-
reported African-American ancestry. The mean (±standard deviation) age at diagnosis was 
56.1 (±11.6) years for European, 51.1 (±10.5) years for Asian and 53.1 (±10.7) years for 
African-American cases. There were ethnic differences in the estimated minor allele 
frequency (MAF) of rs10235235 (Q = 7317.1, 2 df; P for heterogeneity (Phet) = 0). Overall 
MAF for European control women was 0.089 (95% CI 0.087, 0.091), but with strong 
evidence of between-study heterogeneity (Phet = 1x10−22) which was accounted for by the 
three Finnish studies (HEBCS: MAF = 0.15, KBCP: MAF = 0.21 and OBCS: MAF = 0.15; 
Phet = 0.01); no evidence of heterogeneity remained after taking account of these studies 
(MAF = 0.087 (95% CI 0.085, 0.089); Phet = 0.23). Relative to Europeans, overall MAF was 
higher for African-Americans (0.213, 95% CI 0.195, 0.232; Phet = 0.26) but much lower for 
Asians (0.002; 95% CI 0.001, 0.002), with strong evidence of between-study heterogeneity 
for the latter (Phet = 4 × 10−14). 
The case-control analysis was consistent with a modest association between rs10235235 and 
breast cancer risk for women of European ancestry, with an estimated per allele OR of 0.96 
(95% CI 0.93, 0.99; P for linear trend (Ptrend) = 0.02). Genotype-specific ORs were 0.98 (95% 
CI 0.94, 1.01; P = 0.21) for AG vs. AA (Figure 1A) and 0.80 (95% CI 0.69, 0.93; P = 0.004) 
for GG vs. AA (Figure 1B) with no evidence of between-study heterogeneity for either OR 
estimate (Phet = 0.44, I2 = 1.9% and Phet = 0.76, I2 = 0.0% for heterozygote and homozygote 
OR estimates respectively). There was, however, marginally significant evidence that the 
genotypic OR estimates departed from those expected under a multiplicative model with the 
inverse association of the GG genotype being more than the square of that of the AG 
genotype (test for deviation from multiplicative model, P = 0.04). 
Figure 1 Association of rs10235235 with breast cancer risk for women of European 
ancestry. Forest plots of the association of rs10235235 AG (heterozygote) genotype (A) and 
GG (homozygote) genotype (B) with breast cancer risk for women of European ancestry. 
Horizontal lines represent 95% CIs. Square boxes represent study specific fixed-effects 
estimates. The diamond represents the combined, fixed-effects estimate of the OR and 95% 
CI. The vertical line represents the null effect (OR = 1.0) and the dashed vertical line 
represents the estimated heterozygote OR (A) and the estimated homozygote OR (B). 
Homozygote ORs for six studies (CTS, DEMOKRITOS, kConFab/AOCS, NBCS, NBHS and 
RPCI) could not be estimated because there were no GG homozygotes among cases or among 
controls in each of these studies (see Additional file 1: Table S2). 
Data for rs10235235 in women of Asian or African-American ancestry were more limited 
with just two African-American studies (1,046 cases and 932 controls) and nine Asian studies 
(5,795 cases and 6,624 controls). In addition, this SNP was sufficiently rare in Asian 
populations (MAF = 0.002) that we were unable to estimate the heterozygote OR in two 
Asian studies (SEBCS, one carrier among 1,114 cases and no carriers among 1,129 controls; 
TWBCS, one carrier among 236 controls and no carriers among 774 cases, Additional file 1: 
Table S2) and we could not estimate a homozygote OR for any Asian study (Additional file 
1: Table S2). There was no clear evidence that this SNP was associated with breast cancer 
risk for women of Asian (heterozygote OR = 1.06, 95% CI 0.76, 1.49) or African-American 
ancestry (heterozygote and homozygote ORs were OR = 1.09, 95% CI 0.90, 1.32 and OR = 
0.94, 95% CI 0.62, 1.42 respectively; Additional file 1: Figure S1). This analysis, however, 
had low power to detect associations in non-Europeans and these OR estimates were not 
inconsistent with the magnitude of the observed OR estimates for European women (Phet = 
0.51). 
Stratifying cases by ER (Phet = 0.83) or PR (Phet = 0.19) status, tumour grade (Phet = 0.63) or 
nodal involvement at diagnosis (Phet = 0.51) showed no evidence of effect modification 
(Table 1). There was some evidence of effect modification by morphology (Phet = 0.03). For 
ductal cancers we estimated a very modest reduction of risk for heterozygotes (ORhet = 0.98, 
95% CI 0.93, 1.02; P = 0.30) and a stronger, significant reduction for homozygotes (ORhom = 
0.74, 95% CI 0.61, 0.90; P = 0.003). For lobular cancers there was no such trend (ORhet = 
1.07, 95% CI 0.98, 1.17; P = 0.14 and ORhom = 0.91, 95% CI 0.64, 1.27; P = 0.57). 
  
Table 1 Association of rs10235235 with risk of breast cancer for women of European ancestry: stratified analysis 
 Cases Controls ORhet 95% CI P1 ORhom 95% CI P1 Phet 
ER positive 24780 38739 0.99 0.95, 1.03 0.61 0.83 0.70, 0.99 0.04  
ER negative 5851 38739 1.02 0.95, 1.10 0.60 0.60 0.43, 0.86 0.005  
NK 8339         
Total 38970* 38739 0.99 0.95, 1.03 0.74 0.79 0.67, 0.94 0.006 0.83 
PR positive 18497 39033 0.98 0.93, 1.02 0.32 0.82 0.67, 0.99 0.04  
PR negative 8193 39033 1.02 0.96, 1.09 0.53 0.74 0.56, 0.98 0.03  
NK 12111         
Total 38801** 39033 0.99 0.94, 1.03 0.52 0.80 0.67, 0.95 0.01 0.19 
Ductal 22123 31803 0.98 0.93, 1.02 0.30 0.74 0.61, 0.90 0.003  
Lobular 3921 31803 1.07 0.98, 1.17 0.14 0.91 0.64, 1.27 0.57  
other & NK 5995         
Total 32039 31803 0.99 0.95, 1.04 0.64 0.77 0.64, 0.92 0.004 0.03 
grade 1 5944 37285 0.97 0.90, 1.05 0.46 0.86 0.65, 1.15 0.31  
grade 2 13427 37285 1.00 0.95, 1.06 0.92 0.80 0.63, 0.98 0.04  
grade 3 8638 37285 0.98 0.92, 1.05 0.58 0.61 0.46, 0.82 0.001  
NK 8769         
Total 36778 37285 0.99 0.95, 1.03 0.56 0.76 0.64, 0.90 0.001 0.63 
node negative 17463 37836 0.98 0.93, 1.03 0.47 0.86 0.71, 1.04 0.12  
node positive 10746 37836 0.98 0.92, 1.04 0.46 0.72 0.57, 0.93 0.01  
NK 9359         
Total 37568 37836 0.98 0.94, 1.02 0.31 0.81 0.68, 0.96 0.02 0.51 
Association of rs10235235 with risk of breast cancer for women of European ancestry stratified by ER status, PR status, morphology, grade and nodal status. 
ORhet: odds ratio comparing rs10235235 AG genotype versus AA genotype. ORhom: odds ratio comparing rs10235235 GG genotype versus AA genotype. 
P1: test of H0 no association between rs10235235 and breast cancer risk. Phet: test of H0 no difference between stratum specific estimates for variables with two strata; H0 no 
linear trend in stratum specific estimates for variables with three strata. NK: not known. 
*Excludes seven studies that selected all ER negative cases (CTS, DEMOKRITOS, NBCS, NBHS, OSU, RPCI and SKKDKFZS) and one study (PBCS) that selected all ER 
positive cases. 
**Excludes seven studies that selected all PR negative cases (CTS, DEMOKRITOS, NBCS, NBHS, OSU, RPCI and SKKDKFZS). 
The SNP rs10235235 maps to a locus (CYP3A) that has been considered as an a priori 
candidate for involvement in determining age at menopause and age at menarche [21,22]. 
Stratifying cases by age at diagnosis (≤50 or >50 years) as a proxy for menopausal status at 
diagnosis showed no evidence of effect modification (Phet = 0.89, Table 2) and excluding 
cases who were diagnosed between age 46 and 55 as potentially peri-menopausal did not alter 
this result (Phet = 0.28). Data on age at menarche was available for 21,736 cases and 22,686 
controls (Additional file 1: Table S4); to increase the power of the analysis we included 
additional data from BBCS and UKBGS (5,737 cases, 5,572 controls, Additional file 1: Table 
S4) [19]. There was a 1.5% (95% CI 0.5%, 2.7%; P = 0.004) reduction in breast cancer risk 
associated with each additional year’s increase in age at menarche. Mean age at menarche 
was positively associated with number of copies of the minor allele of rs10235235 for 
controls (Ptrend = 0.005, Table 3) but not for cases (Ptrend = 0.97, Table 3). Consequently, there 
was an inverse trend in the magnitude of the heterozygote and homozygote breast cancer ORs 
with mean age at menarche (Phet = 0.02; Table 4); being a carrier of one or two rare alleles of 
rs10235235 was associated with an estimated 16% (ORhet = 0.84, 95% CI 0.75, 0.94; P = 
0.003) or 19% (ORhom = 0.81, 95% CI 0.51, 1.30; P = 0.39) (Ptrend = 0.002) reduction in 
breast cancer risk for women who had their menarche at ages ≥15 years but there was no 
evidence of reduction for those with a menarche at age ≤11 years (ORhet = 1.06, 95% CI 0.95, 
1.19; P = 0.30 and ORhom = 1.07, 95% CI 0.67, 1.72; P = 0.78) (Ptrend = 0.29). There was no 
evidence that the inverse trend in the magnitude of ORs with mean age at menarche differed 
between heterozygous and homozygous carriers (P = 0.97) and no evidence that the trend 
was non-linear (P = 0.70). 
Table 2 rs10235235 and risk of breast cancer for women of European ancestry by age at diagnosis 
Age at diagnosis (years) Cases* Controls* ORhet 95% CI P1 ORhom 95% CI P1 Phet 
≤ 50 11794 34988 0.99 0.93, 1.05 0.69 0.68 0.53, 0.86 0.003  
> 50 23264 34988 0.97 0.93, 1.02 0.24 0.84 0.70, 1.00 0.04  
NK 554         
Total 35612 34988 0.98 0.94, 1.02 0.23 0.79 0.67, 0.92 0.003 0.89 
*Five studies (ABCFS, MARIE, MEC, MTLGEBCS and SASBAC) that selected all cases on the basis of age at diagnosis (Additional file 1: Table S3) were excluded from 
this stratified analysis; two small studies (CTS and NBCS) that had no heterozygote or rare homozygote cases in one of the age stratum were also excluded. 
ORhet: odds ratio comparing rs10235235 AG genotype versus AA genotype. ORhom: odds ratio comparing rs10235235 GG genotype versus AA genotype. 
P1: test of H0 no association between rs10235235 and breast cancer risk. Phet: test of H0 no difference between stratum specific estimates. NK: not known. 
  
Table 3 Association of rs10235235 with age at menarche for women of European ancestry by case-control status 
rs10235235 genotype Cases Age at menarche (years) Ptrend Controls Age at menarche (years) Ptrend 
AA 22954 12.83  23383 12.95  
AG 4312 12.83  4627 13.02  
GG 207 12.83  248 13.05  
Total 27473 12.83 0.97 28258 12.96 0.005 
Ptrend: test of H0 no linear trend in age at menarche according to rs10235235 genotype. 
  
Table 4 rs10235235 and risk of breast cancer for women of European ancestry by age at menarche 
Age at menarche (years) Cases Controls ORhet 95% CI P1 ORhom 95% CI P1 Phet 
≤11 4818 4749 1.06 0.95, 1.19 0.30 1.07 0.67, 1.72 0.78  
12 5655 5720 0.92 0.83, 1.02 0.10 0.83 0.54, 1.28 0.41  
13 7308 7379 0.93 0.85, 1.02 0.11 0.77 0.54, 1.09 0.14  
14 5307 5743 0.96 0.86, 1.06 0.42 0.69 0.45, 1.06 0.09  
≥15 4385 4667 0.84 0.75, 0.94 0.003 0.81 0.51, 1.30 0.39  
Total 27473 28258 0.94 0.90, 0.98 0.007 0.81 0.67, 0.98 0.03 0.02 
ORhet: odds ratio comparing rs10235235 AG genotype versus AA genotype. ORhom: odds ratio comparing rs10235235 GG genotype versus AA genotype. 
P1: test of H0 no association between rs10235235 and breast cancer risk. Phet: test of H0 no linear trend in stratum specific estimates.
Discussion 
This study of more than 47,000 breast cancer cases and 47,000 controls has confirmed that 
rs10235235, mapping to 7q22.1 (CYP3A), is associated with a reduction in breast cancer risk 
for women of European ancestry. Previously, our hypothesis-generating study of 10,000 
breast cancer cases and 17,000 controls found a per allele OR estimate of 0.96 (95% CI 0.90, 
1.02; P = 0.2) with marginally significant evidence of an inverse association for breast cancer 
diagnosed age 50 years or younger (OR = 0.91, 95% CI 0.83, 0.99; P = 0.03) but no evidence 
of an association for breast cancer at later ages (OR = 1.01, 95% CI 0.93, 1.10; P = 0.82) 
[19]. In this considerably larger study, we found a heterozygote OR estimate of 0.98 (95% CI 
0.94, 1.01; P = 0.21) and a homozygote OR estimate of 0.80 (95% CI 0.69, 0.93; P = 0.004) 
with marginally significant evidence that the inverse association for homozygotes is greater 
than predicted by a multiplicative model (P = 0.04). 
To our knowledge rs10235235 is the first SNP to be associated with both breast cancer risk 
and age at menarche, consistent with the well documented association between later age at 
menarche and a reduction in breast cancer risk [23]. Genome-wide association studies have 
identified more than 70 breast cancer risk variants [5,6] and more than 30 variants associated 
with age at menarche [22], none of which map to the CYP3A locus. rs10235235 was 
originally identified on the basis of a highly significant association with hormone levels, 
accounting for 4.9% of the variation in premenopausal urinary E1G levels [19]. In this 
current analysis, rs10235235 accounted for only 0.01% of the variation across controls in age 
at menarche and we estimate that this SNP explains just 0.01% of the familial excess breast 
cancer risk. Thus our data illustrate the potential statistical efficiency of studies of 
intermediate phenotypes in the identification of rarer (MAF < 10%) risk alleles with modest 
associations. Our analysis shows some inconsistency with a recent genome-wide study of 
circulating estradiol, testosterone and sex hormone-binding globulin in postmenopausal 
women [24]. In that study there was no genome-wide significant association observed with 
plasma estradiol levels in either the primary analysis of approximately 1,600 postmenopausal 
women who were not taking postmenopausal hormones at blood draw or the secondary 
analysis that included approximately 900 current postmenopausal hormone users. Further 
studies will be needed to determine whether the lack of an association between CYP3A 
variants and postmenopausal plasma estradiol levels reflects a difference in the menopausal 
status of the study subjects, the hormone/metabolite that was analysed, or chance. 
One possible explanation for the apparent effect modification of the rs10235235 – breast 
cancer risk association by age at menarche is that this is a function of genotyping a marker 
SNP rather than the true causal variant. For example if rs10235235 were perfectly correlated 
with a causal variant, SNP X, with a MAF substantially lower than that of rs10235235 (D’ ~ 
1.0, r2 < 1.0), then there would be three types of chromosome in the population: (i) 
chromosomes carrying the common allele of rs10235235 and the common allele of SNP X, 
(ii) chromosomes carrying the rare allele of rs10235235 and the common allele of SNP X and 
(iii) chromosomes carrying the rare allele of rs10235235 and the rare (protective) allele of 
SNP X. Only chromosomes carrying the rare allele of rs10235235 and the rare (protective) 
allele of SNP X (subset (iii)) would be enriched in controls. Genotyping the marker 
(rs10235235) rather than the causal variant leads to misclassification. As the causal variant is 
associated with a protective effect on breast cancer risk the proportion of chromosomes 
carrying both the rare allele of the causal variant and the marker (type iii) compared to the 
common allele of the causal variant and the rare allele of the marker (type ii) will be greater 
in controls than in cases such that the extent of misclassification will be greater for cases than 
controls. This will attenuate the association between genotype and age at menarche to a 
greater extent in cases than in controls creating an apparent “effect modification”. Fine 
mapping and functional studies will be required to identify the causal variant and to 
determine the true relationship between the causal variant, age at menarche and breast cancer 
risk. 
Despite our original finding of a strong association between rs10235235 and hormone levels 
we found no evidence that the association between this SNP and breast cancer risk differed 
by the hormone receptor status of the tumour, nor did we find any evidence that the 
association differed by stage, grade or lymph node involvement. There was marginally 
significant evidence that the association between rs10235235 and breast cancer risk differed 
between ductal and lobular cancers (Phet = 0.03). Given the number of stratified analyses that 
we carried out (six stratifying variables) and given that there is no biological basis to support 
an interaction between rs10235235 and morphology it seems likely that this is a chance 
observation. 
In contrast to our earlier study [19], we found no evidence of an interaction with age at 
diagnosis when we stratified cases by age ≤/>50 years, either including or excluding cases 
diagnosed between age 46 and 55 years as potentially peri-menopausal. We used age at 
diagnosis as a proxy for menopausal status at diagnosis because menopausal status at 
diagnosis is difficult to determine by questionnaire, especially given the use of hormone 
replacement therapies; while information on age at diagnosis was available for all but 1.4% 
(N = 554) of cases, information on age at natural menopause was missing for 65.6% (N = 
26,552) of cases of European ancestry. Similarly, although rs10235235 is a plausible 
candidate for association with age at menopause we did not test this due to the limited 
amount of data on age at natural menopause for controls of European ancestry (N = 11,294, 
28.2%) and the difficulty in ascertaining whether treatment for breast cancer had influenced 
reported age at menopause for cases. 
Strengths of our study include the large size of this combined analysis and the availability of 
information on tumour characteristics for the majority of cases, and on age at menarche for 
the majority of cases and controls. Limitations include low power of the study to examine an 
association between genotype and breast cancer risk for non-Europeans. 
Conclusions 
In summary, we have confirmed that rs10235235 is associated with breast cancer, we have 
shown for the first time that rs10235235 is associated with age at menarche in controls and 
have suggested a potential mechanism for these associations. It seems likely that rs10235235, 
which maps to the CYP3A locus, tags a causal variant that affects expression of one or more 
CYP3A genes. 
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